- Beraud will also chair newly-formed Brand
Strategy Committee -
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology
company developing a new category of high-performance
neuromodulators for use in treating aesthetic and therapeutic
conditions, today announced the appointment of Jill Beraud to the
company’s Board of Directors. Ms. Beraud brings more than 25 years’
experience building luxury, fashion, beauty, and consumer brands.
Ms. Beraud will also chair a newly-formed Revance Brand Strategy
Committee focused on establishing the company’s innovative
neuromodulator, DaxibotulinumtoxinA for Injection (DAXI), in the
minds of consumers.
“We are delighted to welcome Jill Beraud to our Board at this
pivotal time in our company’s trajectory. She arrives at an ideal
moment as we establish a rarity among biotech companies – a Brand
Strategy Committee dedicated to understanding and embracing the
consumer mindset,” said Dan Browne, President and Chief Executive
Officer (CEO) of Revance. “Jill’s board experience with Levi
Strauss and track record of launching high-growth businesses and
powerhouse consumer brands at firms such as Pepsi, Victoria’s
Secret and Tiffany & Co., will be invaluable as we approach
commercialization. We look forward to working with her to unlock
the true promise of what our long-acting neuromodulator, DAXI, can
deliver.”
As chair of the Revance Brand Strategy Committee, Ms. Beraud
will shape the company’s consumer strategy as it prepares to
meaningfully transform patient experiences. With the help of the
committee, Revance aims to shift how neuromodulators are perceived,
talked about, and ultimately experienced by consumers as a result
of its game-changing science.
Ms. Beraud is currently CEO and Co-Founder of Sh’nnong Beverage
Company, a business creating a line of functional beverages. Prior
to that, she served as CEO of IPPOLITA, a fine jewelry company with
distribution in Bergdorf Goodman, Neiman Marcus, Nordstrom, and
other national retailers. Previously she held the role of Executive
Vice President, Global Retail and e-Commerce, for Tiffany &
Co., where she was responsible for all global retail, operations,
e-commerce, digital, and omni-channel consumer experience. Ms.
Beraud has also managed brands such as Living Proof and
Starbucks/Lipton Joint Ventures, and served as global chief
marketing officer at PepsiCo, where she was responsible for
PepsiCo's $60 billion portfolio of food and beverage brands. She
also spent 13 years at Limited Brands as chief marketing officer of
Victoria's Secret, and Executive Vice President of Marketing for
its broader portfolio of specialty brands, including Bath &
Body Works, Henri Bendel, and Limited Stores. Further, she has a
long history of serving on boards of renowned brands, such as Levi
Strauss & Co. and Elizabeth Arden Holdings. Ms. Beraud was
named to Fast Company’s “Most Creative People in Business” in
2013.
“Over the years, I have had the opportunity to launch brands
that have broken the mold in terms of quality and experience, said
Ms. Beraud. “Today, consumers want and deserve more from their
chosen products and services. DAXI has the opportunity to change
the game in neuromodulation and I am thrilled to be a part of the
team that will help redefine outcomes in the space.”
About Revance Therapeutics, Inc.
Revance Therapeutics is a biotechnology company focused on
developing transformative neuromodulators to address a broad
spectrum of aesthetic and therapeutic conditions. Revance’s lead
product candidate, DaxibotulinumtoxinA for Injection (DAXI),
utilizes a unique proprietary peptide excipient technology combined
with highly purified botulinum toxin type A to produce a novel,
long-acting neuromodulator. In aesthetics, Revance successfully
completed its Phase 3 program for DAXI in glabellar (frown) lines
and is currently pursuing U.S. regulatory approval in 2020, while
also running two separate Phase 2 studies in forehead lines and
lateral canthal lines (crow’s feet). In therapeutics, DAXI is being
studied in three indications, including a Phase 3 trial in cervical
dystonia, a Phase 2 trial in adult upper limb spasticity, and a
Phase 2 trial in plantar fasciitis, with plans to also study
migraine. Beyond DAXI, Revance also has begun development of a
biosimilar to BOTOX®, which would compete in the existing
short-acting neuromodulator marketplace. More information on
Revance may be found at www.revance.com.
“Revance Therapeutics” and the Revance logo are registered
trademarks of Revance Therapeutics, Inc.BOTOX® is a registered
trademark of Allergan, Inc.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements related to the process and timing of, and
ability to complete, current and anticipated future clinical
development of our investigational drug product candidates, the
initiation, design, timing and results of our clinical studies
statements about our business and brand strategy, including with
respect to consumer perception and experiences relating to
neuromodulators and/or our potential products, timeline and other
goals and market for our anticipated products, plans and prospects;
including our plans and timing, and potential regulatory approach
and product launch, with respect to our product candidates;
statements about potential benefits of our drug product candidates
and our excipient peptide and other technologies.
Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
from our expectations. These risks and uncertainties include, but
are not limited to: the outcome, cost, and timing of our product
development activities and clinical trials; the uncertain clinical
development process, including the risk that clinical trials may
not have an effective design or generate positive results; our
ability to obtain and maintain regulatory approval of our drug
product candidates; our ability to obtain funding for our
operations; our plans to research, develop, and commercialize our
drug product candidates; our ability to achieve market acceptance
of our drug product candidates; unanticipated costs or delays in
research, development, and commercialization efforts; the
applicability of clinical study results to actual outcomes; the
size and growth potential of the markets for our drug product
candidates; our ability to successfully commercialize our drug
product candidates and the timing of commercialization activities;
the rate and degree of market acceptance of our drug product
candidates; our ability to develop sales and marketing
capabilities; the accuracy of our estimates regarding expenses,
future revenues, capital requirements and needs for financing; our
ability to continue obtaining and maintaining intellectual property
protection for our drug product candidates; and other risks.
Detailed information regarding factors that may cause actual
results to differ materially from the results expressed or implied
by statements in this press release may be found in Revance's
periodic filings with the Securities and Exchange
Commission (the "SEC"), including factors described in the
section entitled "Risk Factors" of our of our annual report on Form
10-Q filed May 9, 2019. These forward-looking statements speak only
as of the date hereof. Revance disclaims any obligation to update
these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190606005149/en/
INVESTORSRevance Therapeutics, Inc.:Jeanie Herbert,
714-325-3584jherbert@revance.comorGilmartin Group, LLC.:Laurence
Watts, 619-916-7620laurence@gilmartinir.com
MEDIAGeneral Media:Y&R:Jenifer
Slaw347-971-0906jenifer.slaw@YR.comorTrade Media:Nadine Tosk,
504-453-8344nadinepr@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Sep 2023 to Sep 2024